N@N

PHARMASSET INC (NASDAQ:VRUS), Up By 72.65% ($56.47) From $77.730 After BUYINS.NET Report Predicted Strength Before Earnings

^{Published on 2011-11-21 11:42:28 - WOPRAI}
 

November 21, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, October 19th 2011 stating that PHARMASSET INC (NASDAQ:VRUS) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=vrus&id=201662

At the time this story was written, PHARMASSET INC (NASDAQ:VRUS) is Up By 72.65% ($56.47) From $77.730 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

PHARMASSET INC (NASDAQ:VRUS) - Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including RG7128, an HCV cytosine nucleoside polymerase inhibitor; PSI-7977, an HCV uracil nucleotide analog polymerase inhibitor, which in Phase IIb clinical trial; and PSI-938, an HCV guanine nucleotide analog polymerase inhibitor, which in Phase Ib clinical trial. It is also developing PSI-661, an HCV guanine nucleotide analog polymerase inhibitor; and PSI-7977, PSI-938, and PSI-661. In addition, the company is developing Racivir for the treatment of human immunodeficiency virus. It has a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the development of PSI-6130 and its prodrugs, including RG7128. The company also has collaboration and licensing agreements with University of Cincinnati; Apath, LLC; and Emory University. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. PHARMASSET INC (NASDAQ:VRUS) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net